These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33101763)

  • 1. Ziconotide-Induced Oro-lingual Dyskinesia: 3 Cases.
    Grajny K; Durphy J; Adam O; Azher S; Gupta M; Molho E
    Tremor Other Hyperkinet Mov (N Y); 2020 Oct; 10():37. PubMed ID: 33101763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal ziconotide for complex regional pain syndrome: seven case reports.
    Kapural L; Lokey K; Leong MS; Fiekowsky S; Stanton-Hicks M; Sapienza-Crawford AJ; Webster LR
    Pain Pract; 2009; 9(4):296-303. PubMed ID: 19500276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziconotide.
    Strigenz T
    J Pain Palliat Care Pharmacother; 2014 Mar; 28(1):73-4. PubMed ID: 24397285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
    Rauck RL; Wallace MS; Leong MS; Minehart M; Webster LR; Charapata SG; Abraham JE; Buffington DE; Ellis D; Kartzinel R;
    J Pain Symptom Manage; 2006 May; 31(5):393-406. PubMed ID: 16716870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
    Dupoiron D; Bore F; Lefebvre-Kuntz D; Brenet O; Debourmont S; Dixmerias F; Buisset N; Lebrec N; Monnin D
    Pain Physician; 2012; 15(5):395-403. PubMed ID: 22996851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyskinesia caused by ziconotide-baclofen combination in an adolescent affected by cerebral palsy.
    Pozzi M; Piccinini L; Giordano F; Carnovale C; Perrone V; Pellegrino P; Antoniazzi S; Turconi AC; Radice S; Clementi E
    Reg Anesth Pain Med; 2014; 39(2):172-3. PubMed ID: 24513956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administering ziconotide and monitoring patients treated with ziconotide: expert opinions.
    Mitchell AA; Sapienza-Crawford AJ; Hanley KL; Lokey KJ; Wells L; McDowell GC; Stanton-Hicks M
    Pain Manag Nurs; 2013 Sep; 14(3):e84-94. PubMed ID: 23972874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A safety review of approved intrathecal analgesics for chronic pain management.
    Chalil A; Staudt MD; Harland TA; Leimer EM; Bhullar R; Argoff CE
    Expert Opin Drug Saf; 2021 Apr; 20(4):439-451. PubMed ID: 33583318
    [No Abstract]   [Full Text] [Related]  

  • 12. Italian registry on long-term intrathecal ziconotide treatment.
    Raffaeli W; Sarti D; Demartini L; Sotgiu A; Bonezzi C;
    Pain Physician; 2011; 14(1):15-24. PubMed ID: 21267038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
    Wallace MS
    Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations for the management of chronic pain by intrathecal ziconotide].
    Tronnier V; Hofacker W; Ilias W; Kleinmann B; Koulousakis A; Kress HG; Likar R; Lux EA; Müller-Schwefe G; Schütze G; Uberall M
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():106-9. PubMed ID: 21595155
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).
    Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC
    Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziconotide-induced psychosis: a case report.
    Phan SV; Waldfogel JM
    Gen Hosp Psychiatry; 2015; 37(1):97.e11-2. PubMed ID: 25459190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy.
    Prusik J; Argoff C; Peng S; Pilitsis JG
    Neuromodulation; 2017 Jun; 20(4):386-391. PubMed ID: 27492135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziconotide: a clinical update and pharmacologic review.
    Pope JE; Deer TR
    Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.